IL1F10 and triple-A syndrome: IL‐38 treatment reduced M1 macrophage accumulation in the aortic wall (Figure 2a–d), which reduced the incidence of AAA formation (Figure 3), indicating that IL‐38 treatment may be a novel therapy for AAA patients.